Cytokine Signalling Forum

Publications





November 20

Incidencia Basada en Edad (<65 vs ≥65 años) de Infecciones y Infecciones Graves con Tofacitinib versus DMARDs Biológicos en los Ensayos Clínicos en Artritis Reumatoide en los EE.UU. y en el Registro Corrona RA

Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H.
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992

Reports from clinical trials and the US Corrona RA registry showed that serious infection event (SIE) incidence was higher in older versus younger patients with RA receiving 10 mg BID of TOF and ADA, however, SIE risk was similar between age groups with TOF 5 mg BID and ADA. Data were collected from Phase II–IV tofacitinib studies, and the US Corrona RA registry. The clinical data set evaluated patients receiving TOF 5 and 10 mg BID versus TNFi (ADA/ETN) in RA patients aged ≥50 years. ...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor Kos

September 20

Tasas de Incidencia de Eventos de Enfermedad Intersticial Pulmonar en Pacientes con Artritis Reumatoide Tratados con Tofacitinib

Citera G, Mysler E, Madariaga H, Cardiel M H, Castaneda O, Fischer A, Richette P, Chartrand S, Park J K, Strengholt S, Rivas J L, Thorat A V, Girard T, Kwok K, Wang L.
Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.

This study highlights the importance of accounting for known risk factors of RA-ILD in clinical practice. Interstitial lung disease (ILD) is an extra-articular manifestation of RA. The post-hoc investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. This post-hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 21 Phase 1-4, and 2 long-term e...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor Koz